		Observations	1943	Patient ID 1410 corresponds to a duplicate registration for which r	no data was collected and therefore excluded
Member Type	DATA	Variables	43	Unless otherwise indicated, blank fields indicate missing values	
				Note: Primary analysis includes all cases	
List of Variables	and Attributes				
#	Variable	Туре	Len	Label	Codes
1	prot	Char	5	ECOG-ACRIN protocol number	
2	group_uid	Num	8	A blinded ID generated by ECOG-ACRIN	
3	uid	Num	8	Original blinded ID	
4	ethnicity	Num	3	NCI Ethnicity	1=Hispanic, 2=Non-Hispanic, 11=Institution Refusal, 12=Not Reported
5	ncirace	Num	3	NCI Race	1=white, 3=African-American, 4=Asian, 5=Hawaiian/Pacific Islander, 6=Native American, 11=Other
F	cancl	Num	2	Reason Withdrew before Treatment	blank = did not withdraw, 1=patient refused treatment, 3=ineligible, 8=other, 11=progressed before treatment
	arm	Char		Treatment Arm	A=Sunitinib, B=Sorafenib, C=Placebo
	OFF TX REAS	Num	_	Off Treatment Reason	See below
	ps	Num		Performance Status Prior to Surgery	See Below
	dosegrp	Num		Starting Dose Group	1=Started at Full Dose, 2=Started at Reduced Dose
	cycles	Num		Total Cycles	Total ted at 1 am 2000, 2 otal ted at Neddoca 2000
	age	Num		Age (Yrs)	
	pathtstgnum	Num		Path T Stage Number	1 = T1, 2 = T2, 3 = T3, 4 = T4
	pathnstg	Char		Path N Stage	0 = N0, 1 = N1, 2 = N2, X = NX
	pathmstg	Char		Path M Stage	0 = M0, 1 = M1, X = MX
	fuhrman	Num		Fuhrman Grade	1 = Grade 1, 2 = Grade 2, 3 = Grade 3, 4 = Grade 4
17	prim surg type	Num	3	Type of Nephrectomy (Radical vs Partial)	1=Radical, 2=Partial
18	dose_per_prot	Num	3	Full Prot Dose at Cycle 3?	0=no, 1=yes
19	dead	Num	3	Survival Status (1=deceased)	0=alive/censored, 1=dead
20	dfsevent	Num	3	Disease-Free Survival Event	0=no, 1=yes
21	dfsmos	Num	8	Disease-Free Survival Time (Months)	
22	firstev	Num	3	Type of First DFS Event	1=Recurrence, 2=Second Primary, 3=Death without Recurrence or Second Primary, 4=Metastatic Disease at Diagnosis, 0=Censored
	ajccstage	Num		AJCC Stage	1 = Stage 1, 2 = Stage 2, 3 = Stage 3, 4 = Stage 4
	sex	Num		Sex	1=male, 2=female
	var1	Char	1	STRATIFICATION VAR 1	Risk Category: 1=Intermediate High Risk,2=Very High
	var2	Char		STRATIFICATION VAR 2	Histology: 1=Clear Cell, 2=Other
	var3	Char		STRATIFICATION VAR 3	Performance Status: 1=PS 0, 2=PS 1
	var4	Char		STRATIFICATION VAR 4	Surgical Approach: 1=Laparoscopic, 2=Open

20	sorafmgp	Num	c	Sum of Soraf/Pbo Doses Prescribed Day 1 Each Cycle (mg)	
	sorafmg	Num		Sum of Soraf/Pbo Doses Recorded as Taken by Pt (mg)	
	sorafmg			Total Soraf/Pbo Dose Taken Divided by Number of Cycles (mg)	
	sorafpct	Num Num		Percent of Prescribed Soraf/Pbo Dose Taken	
		_		Sum of Sunit/Pbo Doses Prescribed Day 1 Each Cycle (mg)	
	sunitmgp	Num		Sum of Sunit/Pbo Doses Prescribed Day 1 Each Cycle (mg) Sum of Sunit/Pbo Doses Recorded as Taken by Pt (mg)	
	sunitmg	Num			
	sunitavg 	Num		Total Sunit/Pbo Dose Taken Divided by Number of Cycles (mg)	
	sunitpct 	Num		Percent of Prescribed Sunit/Pbo Dose Taken	
	recursite	Num	_	Site of Recurrence	See below
38	txdurmos	Num	8	Treatment Duration (Months)	
	renal_histol	Num		Histology	1=Clear Cell, 2=Papillary, 3=Chromophobe, 4=Mixed, >25% Clear, 5=Mixed, <25% Clear, 6=Unclassified
	sarco_feat_yn	Num		Sarcomatoid Features?	1=No, 2=Yes
	surg_meth	Num		Surgical Approach per Surgeon (Open vs Lap)	1=Open, 2=Laparoscopic
	survmos	Num		Survival Time (Months)	
43	toxflag	Num	8	Toxicity Assessed Flag	1=Included in Safety Analysis, 0 otherwise
Formats:					
Off Treatment F					
	1=Complete per Protocol				
2=Disease Progr					
3=Adverse Even	ts				
4=Death					
5=Patient Withd	rawal/Refusal				
6=Alternative Therapy					
7=Other Compli	cating Disease				
99=Other					
Sites of Recurre	nce	1			
1=Lung			1		
2=Liver					
3=Central Nervo	•				
4=Subcutaneous	/Lymph Node		1		
5=Skeletal					
6=Renal Bed					
7=Other Organs					
8=Other					
9=Unknown					